MIDDLE EAST AND TURKEY CHRONIC LIVER DISEASE (CLD) THERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Chronic liver disease is associated with the progressive destruction of liver parenchyma for longer period of time (6 months) leading to liver fibrosis and cirrhosis. The main etiology of CLD include alcohol induced liver, hepatitis virus (B, C, and D), hepatocellular carcinoma (HCC), liver cancer, and fatty liver diseases. The treatment for chronic liver diseases include chemotherapy, targeted therapy, vaccines, immunoglobulin, and others. Market players such as IceCure Medical, BioLineRx Ltd., Oramed Pharmaceuticals Inc., and BioLineRx Ltd. are engaged in the development of novel treatment options for CLD.

Middle East and Turkey chronic liver disease therapeutics market is estimated to be valued at USD 31.6 Bn in 2026 and is expected to reach USD USD 46.7 Bn by 2033, exhibiting a CAGR of 5.8% during the forecast period (2026-2033).

Market Dynamics

The increasing incidence of liver disease, growing geriatric population, Government and non-government awareness programs related to liver disease, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Middle East and Turkey chronic liver disease therapeutics market over the forecast period.

According to National Library of Medicine, in the Middle East, the prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing, with associated risk factors including Obesity, and type 2 Diabetes. The patient’s progress to develop Nonalcoholic Steatohepatitis (NASH) is about 20% to 30%. Younossi, a nationally recognized leader specializing in hepatology and gastroenterology, reported that in Middle East the prevalence to be highest (33%) in a meta-analysis on Global Epidemiology of NAFLD. Awareness with suspected NAFLD has increased over last two decades, but 95% of the patients are still unaware about having liver disease.

Key features of the study

• This report provides an in-depth analysis of the Middle East and Turkey chronic liver Disease (CLD) therapeutics market, provides market size (USD Bn), and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Middle East and Turkey chronic liver disease (CLD) therapeutics market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi S.A, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc., and Pfizer Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
• Middle East and Turkey chronic liver disease (CLD) therapeutics market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Turkey chronic liver disease (CLD) therapeutics market

Market Segmentation

• By Disease Type
  • Hepatitis
  • Alcohol Induced Liver Disease
  • Liver Cancer
  • Fatty Liver Disease
  • Others
• By Drug Class
  • Chemotherapy Drugs
  • Targeted therapy
  • Vaccines
  • Immunoglobulin
  • Others
• By Route of Administration
  • Oral
  • Parenteral
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country Insights
  • Turkey
  • Saudi Arabia
  • Israel
  • UAE
  • Egypt
  • Rest of Middle East and Turkey
• Key Players Insights
  • Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Swedish Orphan Biovitrum AB
  • GlaxoSmithKline Plc
  • Sanofi S.A
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Abbott Laboratories
  • AstraZeneca plc
  • Pfizer Inc.